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Abstract
the epidemiology of Candida infections has changed
over the last two decades: the number of patients suf-
fering from such infections has increased dramatically
and the Candida species involved have become more
numerous as Candida albicans is replaced as an infect-
ing agent by various non-C.  albicans species (nac).
at the same time, additional antifungal agents have be-
come  available.  the  different  candida  species  may
vary in their susceptibility for these various antifun-
gals. this draws more attention to in vitro susceptibili-
ty testing. unfortunately, several different test meth-
ods exist that may deliver different results. Moreover,
clinical breakpoints (cBP) that classify test results into
susceptible, intermediate and resistant are controver-
sial between clsI and Eucast. therefore, clinicians
should be aware that interpretations may vary with the
test system being followed by the microbiological lab-
oratory.  thus,  knowledge  of  actual  MIc  values  and
pharmacokinetic  properties  of  individual  antifungal
agents is important in delivering appropriate therapy
to patients
IntRoductIon
In  2001,  Mcneil  et  al.  reported  that  (in  the  usa)
“from  1980  through  1997,  the  annual  number  of
deaths in which an invasive mycosis was listed on the
death  certificate  (multiple-cause  mortality)  increased
from 1557 to 6534” (table 1, fig. 1) [1]. augmentation
of fungal infections had been published earlier i.e. by
Beck-sague and Jarvis [2] and Edmond et al. [3] for
the usa and by lamagni et al. [4] for England and
Wales (fig. 2). there are several possible reasons for
this change. an important one might be the increase
in lifespan in the populations of the developed world
and the age related loss of immune-competence. an
increase of systemic fungal infections is probably also
due to more intensive treatment schemes for hemato-
logical  and  oncological  patients  causing  prolonged
neutropenic phases. finally, more effective antibacteri-
al treatments allow patients with infections to survive
longer without necessarily overcoming the underlying
diseases  and  thus  leaving  them  susceptible  to  other
opportunistic infections. Eggimann et al. [5] summa-
rized prior surgery, acute renal failure, previous yeast
colonization,  neutropenia,  antibacterial  therapy,  par-
enteral nutrition, and central venous catheters as risk
factors for invasive candidia infections.
cHangE In EPIdEMIology
the increase in incidence of Candida infections barely
preceded  the  introduction  of  fluconazole  in  1990.
this azole agent combined good activity against Can-
dida albicans with reduced toxicity as compared to i.e.
polyene anti-fungals. It is orally and parentally avail-
able and has a reliable that means linear pharmacoki-
netic profile [6], which makes it easy to handle. not
surprisingly, fluconazole became the agent of choice
for many fungal infections as well as for prophylactic
purposes,  at  that  time  often  being  applied  in  rather
low  doses.  although  there  is  inconclusive  evidence,
many experts in the field believe that it was the selec-
tive pressure exerted by this therapeutic concept that
caused changes in the epidemiology [7]. While in earli-
er years, C. albicans was responsible most of the inva-
sive fungal infections (table 2) [8], gradually more and
more non-C.  albicans species (nac) were found as
offending agents (table 3) [9-16]. While the data show
similar tendencies in the prevalence of various Candi-
da ssp. worldwide, considerable differences can be ob-
served as well. However, these do not lend themselves
to further interpretation since significant differences
in the demographics of the patients observed seem to
be obvious. this change in prevalence of various Can-
dida spp. is nevertheless of clinical importance, since
individual species vary in their susceptibility to various
antifungal agents. While national and international sur-
veillance is important to recognize trends in epidemi-
ology  it  is,  however,  of  utmost  importance  to  gain
knowledge about the local epidemiology as this infor-
mation should guide the empiric therapy of patients. 
suscEPtIBIlIty tEstIng
some of the already cited and many other studies have
also reported on the in-vitro susceptibility of Candida
spp. for various reasons it is difficult to assess the vari-
ous results. there are currently several test methods for
performing  these  assays.  standardized  methods  have
been  published  by  the  clinical  and  laboratory  stan-
dards Institute (clsI) of the usa [17, 18] and by the
European  committee  on  antimicrobial  susceptibility
testing (Eucast) [19]. the two broth dilution meth-
ods are not identical as methodological differences in-
clude  glucose  concentration,  inoculum  size,  shape  of
microtitration wells (flat or round), and end-point read-
ing (visual or spectrophotometric). However, it appears
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Table 1. Ranking of underlying causes of deaths due to infectious diseases in the united states in 1980 and 1997 [1].
1980 1997
Rank type of infection no. of deaths type of infection no. of deaths
1 Respiratory tract 56,966 Respiratory tract 87,181
2 septicemia 9,438 septicemia 22,396
3 Kidney/utI 8,006 HIv/aIds 16,524
4 Heart 2,486 Kidney/utI 13,413
5 tuberculosis 2,333 Heart 5,577
6 Bacterial meningitis 1,402 Hepatobiliary 4,596
7 gastrointestinal 1,377 Mycoses 2,370
8 Hepatobiliary 1,277 tuberculosis 1,259
9 Perinatal 1,035 gastrointestinal 1,053
10 Mycoses 828 Perinatal 820
note: categories of infectious diseases identified by anatomic site rather than by causative microorganism did not have any microor-
ganism specified in the death-certificate data. utI = urinary tract infedtion.
Table 2. species distribution of candida from cases of invasive candidiasisa [8].
species
% of total casesb
1997-1998 1999 2000 2001 2002 2003
C. albicans 73.3 69.8 68.1 65.4 61.4 62.3
C. glabrata 11.0 9.7 9.5 11.1 10.7 12.0
C. tropicalis 4.6 5.3 7.2 7.5 7.4 7.5
C. parapsilosis 4.2 4.9 5.6 6.9 6.6 7.3
C. krusei 1.7 2.2 3.2 2.5 2.6 2.7
C. guilliermondii 0.5 0.8 0.8 0.7 1.0 0.8
C. lusitaniae 0.5 0.5 0.5 0.6 0.5 0.6
C. kefyr 0.2 0.4 0.5 0.4 0.4 0.5
C. rugosa 0.03 0.03 0.2 0.7 0.6 0.4
C. famata 0.08 0.2 0.5 0.2 0.4 0.3
C. inconspicua 0.08 0.1 0.2 0.3
C. novegensis 0.08 0.1 0.07 0.1
C. dubliniensis 0.01 0.08 0.1 0.05
C. lipolytica 0.06 0.06 0.06 0.08
C. zeylanoides 0.03 0.08 0.02 0.04
C. pelliculosa 0.06 0.05 0.04
Canida spp. 3.9 6.0 3.7 3.3 7.9 4.9
total no. of cases 22,533 20,998 11,698 21,804 24,680 33,002
adata compiled from the aRtEMIs dIsK surveillance Program, 1997 to 2003 (221).
bIncludes all specimen types and all hospitals from a total of 127 different institutions in 39 countries.
ccandida species not otherwise identified.
Fig.  1.  Mortality  in  the  united
states, 1980-1997, due to candidiasis,
and other mycoses in persons infect-
ed  and  persons  not  infected  with
HIv [1].
R
a
t
e
 
p
e
r
 
1
0
0
,
0
0
0
 
p
o
p
u
l
a
t
i
o
n
Year
Candidiasis
Candidiasis with HIV
Aspergillosis
Aspergillosis with HIV
Other Mycoses
Other Mycoses
with HIV
7) Rodloff_Umbruchvorlage  23.03.11  12:41  Seite 188that  they  result  in  similar  MIc  levels  for  polyenes,
azoles and echinocandins for identical isolates with a
few noted exceptions [20-23]. this is especially true if
isolates with defined resistance mechanisms are being
tested [22, 23]. However, some “drug/bug” combina-
tions seem to offer particular test problems i.e. caspo-
fungin and C. glabrata [22]. Moreover, Eucast (and
for that matter Etest) results have a tendency for one to
two dilution steps lower MIc values [20, 23]. there are
also some commercially available test devices that have
been tested in their performance. a high degree of cor-
relation with the reference methods was found for the
Etest  by  various  authors  [22,  23].  the  percentage  of
strains classified as resistant in  vitro by the Eucast
procedure and as susceptible in vitro by the vItEK 2
system was 2.6%, and as resistant by the clsI method
and as susceptible by the vItEK 2 was 1.6% (very ma-
jor error) [24]. the difference observed for the vitek 2
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Table 3. species distribution of candida in blood stream infections in various studies.
Reference 9 artemis 10 sentry 11 Horn 12 ostrosky 13 cisterna 14 arendrup 15 fleck 16 Borg
year 2005-2007 2008-2009 2004-2008 1995/1999 2008-2009 2004-2009 2004-2006 2004-2005
location worldwide worldwide usa usa spain denmark germany germany
n 88647 1354 2019 2000 984 2901 512 561
C. albicans 65 48.4 45.6 36.7 49.1 57.1 43 58.5
C. glabrata  11.7 18.2 26 22.9 13.6 21.1 31.3 19.1
C. tropicalis  8 10.6 8.1 15.4 10.8 4.8 11.7 7.5
C. parapsilosis 5.6 17.1 15.6 19.6 20.7 3.7 5.7 8
C. krusei  2.5 2 2.5 2.5 2.1 4.1 3.7 1.4
C. guilliermondii 0.6 0.3 1.1
C. lusitaniae 0.6 0.8 1 ≤1 0.2
C. kefyr  0.6 ≤1
C. inconspicua  0.3 ≤1 1.1
C. famata 0.3 ≤1 0.7
C. rugosa  0.2 0.2
C. dubliniensis 0.2 0.4 0.9 2.6 1.1
C. norvegensis 0.1 0.4
C. lipolytica  0.06 ≤1
C. sake  0.08 ≤1
C. pelliculosa 0.05
C. apicola 0.06
C. zeylanoides 0.02
C. valida  0.01 ≤1
C. intermedia 0.01 ≤1 0.4
C. pulcherrima  <0.01
C. haemulonii <0.01
C. stellatoidea <0.01
C. utilis <0.01 ≤1 0.4
C. humicola  <0.01
C. lambica  <0.01
C. ciferrii <0.01
C. colliculosa <0.01 ≤1 0.4
C. holmii  <0.01
C. marina <0.01
C. sphaerica  <0.01
Candida spp. 4 0.7 3.6 5.1 4.7
Fig. 2. annual rates of candidosis labora-
tory reports, by sex (England and Wales:
1990-9) [4].
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that there are differences in clinical breakpoints (cBP)
suggested by the two organizations. However these re-
sults indicate that although the cBP of Eucast and
clsI  are  significantly  different,  currently  only  few
strains are affected by this difference.
cBP are used to classify MIc results into suscepti-
ble (s), intermediate (I) (clsI for some strange reason
“susceptible  dose  dependent”;  s-dd),  and  resistant
(R), respectively. this has complicated to assess and
compare studies were only percentages of s, I and R
are  published.  the  same  is  true  for  published
MIc50/90 values, as very different MIc distributions
might be behind these numbers. to illustrate this fur-
ther, two very different fictitious distributions result-
ing  in  the  same  MIc50/90  values  are  given  with 
figure  3.  therefore,  meaningful  surveillance  data
should be published as MIc distributions. that allows
for evaluation of the results even at a later date when
i.e.  cBP  had  been  changed  as  has  happened  in  the
past. to circumvent the problem with differences in
cBP published by various organizations, it has been
suggested  to  use  epidemiological  cut  -off  values  to
distinguish between wild type (Wt) organisms without
any resistance mechanisms and non-wild type (n-Wt)
strains  with  higher  MIc  values  that  are  thought  or
known  to  possess  a  resistance  mechanism  [22,  25].
this would put in vitro test results on the safe side as
long as the particular species is a target for the anti-
fungal agent in question. obviously, cBP should not
divide Wt distributions as this will cause arbitrary test
results. Monitoring the development of n-Wt strains
in surveillance studies allows one to analyze the spread
of resistance mechanisms.
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Table 4. In vitro susceptibilities of candida spp. to fluconazole and voriconazole as determined by clsI disk diffusion testinga [9].
fluconazoleb voriconazoleb
species no. of isolates % s % R no. of isolates % s % R
C. albicans 128,625 98.0 1.4 125,965 98,5 1.2
C. glabrata 23,305 68.7 15.7 22,968 82.9 10.0
C. tropicalis  15,546 91.0 4.1 15,198 89.5 5.4
C. parapsilosis 12,788 93.2 3.6 12,453 97.0 1.8
C. krusei  5,079 8.6 78.3 5,oo5 83.2 7.6
C. guilliermondii 1,410 73.5 11.4 1,375 90.5 5.7
C. lusitaniae 1,233 92.1 5.4 1,215 96.7 2.0
C. kefyr  1,044 96.5 2.7 1,032 98.7 0.9
C. inconspicua  566 22.6 53.2 563 90.6 3.9
C. famata 622 79.1 10.3 606 90.3 5.0
C. rugosa  603 49.9 41.8 580 69.3 21.2
C. dubliniensis 310 96.1 2.6 308 98.4 1.0
C. norvegensis 248 41.9 40.7 247 91.5 4.0
C. lipolytica  130 66.2 28.5 128 77.3 14.1
C. sake  87 85.1 11.5 87 92.0 6.9
C. pelliculosa 87 89.7 6.9 86 94.2 4.7
C. apicola 57 98.2 1.8 57 98.2 1.8
C. zeylanoides 70 67.1 24.3 67 85.1 6.0
C. valida  21 23.8 61.9 22 81.8 13.6
C. intermedia 24 95.8 4.2 25 100.0 0.0
C. pulcherrima  14 100.0 0.0 14 100.0 0.0
C. haemulonii 9 88.9 11.1 9 88.9 11.1
C. stellatoidea 7 85.7 0.0 7 85.7 14.3
C. utilis 6 83.3 0.0 7 100.0 0.0
C. humicola  6 50.0 50.0 6 50.0 33.3
C. lambica  5 0.0 80.0 5 40.0 20
C. ciferrii 2 50.0 50.0 2 50.0 0.0
C. colliculosa 2 100.0 0.0 2 100.0 0.0
C. holmii  1 100.0 0.0 1 100.0 0.0
C. marina 1 0.0 0.0 1 100.0 0.0
C. sphaerica  1 100.0 0.0 1 100.0 0.0
Candida spp. 9,744 86.2 8.9 9,577 93.6 4.1
aIsolates were obtained from 133 istitutions, 2001 tp 2007.
bfluconazole and voriconazole disk diffusion testing was performed in accordance with clsI document M44-a (7). the interpretive
breakpoint (zone diameters) were as follows: s, ≥19 mm (fluconazole) and ≥ 17 min (voriconazole); R, ≤14 mm (fluconazole) and
≤ 13 mm (voriconazole).
ccandida species, not otherwise specified.
Fig. 3. two very different fictitious MIc distributions result-
ing in the same MIc50/90 values: 2 and 32 mg/l
7) Rodloff_Umbruchvorlage  23.03.11  12:41  Seite 190REsIstancE MEcHanIsMs
a  number  of  different  resistance  mechanisms  have
been  described  in  Candida spp.    often,  several  of
these mechanisms are combined to result in a stepwise
development  of  clinically  relevant  resistance.  Resis-
tance to i.e. fluconazole can be caused i.e. by alter-
ations in sterol biosynthesis, by mutations in the drug
target enzyme, sterol 14α-demethylase, which lowers
its affinity for fluconazole, by increased expression of
the ERg11 gene encoding for this enzyme, or by over-
expression of genes coding for membrane transport
proteins  of  the  aBc  transporter  (CDR1/CDR2)  or
the major facilitator (MDR1) superfamilies [26]. 
similarly Candida isolates were found with reduced
susceptibility  to  echinochandins  that  showed  muta-
tions in selected regions of fks1, the gene encoding
the echinocandin target enzyme 1-3-b-d-glucan syn-
thase [27]. In particular, mutations of the serine at po-
sition 645 and also, in some cases, at position  641
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Table 5. In vitro susceptibilities of 5,346 clinical isolates of Candida spp. to anidulafungin, caspofingin, and micafungin [38].
organism no.ofisloates antifungal cumulative % of isolates susceptible at a MIc (ﾵg/ml) ofa
tested  agent 0.007 0.015 0.03 0.06 0.12 0.25 0.5 124 ≥8
C. albicans 2,869 anidulafungin 6.2 33.5 69.5 92.4 99.1 99.5 99.5 99.6 100.0
caspofungin 1.7 26.7 74.2 97.1 99.3 99.9 100.0
Micafungin 11.9 80.6 96.4 99.3 99.4 99.5 99.6 100.0
C. parapsilosis 759 anidulafungin 0.3 0.3 0.3 1.4 4.7 27.9 92.5 100.0
caspofungin 0.1 0.5 3.3 10.7 52.2 89.5 98.6 99.9 100.0
Micafungin 0.1 0.3 0.3 0.5 6.1 24.4 79.3 100.0
C. glabrata  747 anidulafungin 0.4 7.8 62.4 93.6 99.4 99.7 99.9 99.9 100.0
caspofungin 7.0 65.2 95.3 98.4 99.2 99.7 99.9 99.9 99.9 100.0
Micafungin 13.7 91.4 97.9 98.9 99.5 99.9 99.9 100.0
C. tropicalis 625 anidulafungin 3.2 24.2 75.7 95.0 98.4 99.4 99.5 99.5 100.0
caspofungin 1.3 31.0 79.7 97.3 99.0 99.7 99.7 99.8 99.8 99.8 100.0
Micafungin 4.0 39.5 77.6 96.3 98.6 99.5 99.7 100.0
C. krusei 136 anidulafungin 2.9 47.1 90.4 99.3 99.3 100.0
caspofungin 0.7 0.7 41.9 75.7 94.9 99.3 100.0
Micafungin 2.2 13.2 85.3 96.3 100.0
C. guilliermondii 61 anidulafungin 3.3 6.6 13.1 57.4 90.2 100.0
caspofungin 1.6 4.9 11.5 39.3 80.3 95.1 95.1 95.1 100.0
Micafungin 3.3 3.3 6.6 11.5 21.3 65.6 98.4 100.0
C. lusitaniae 58 anidulafungin 1.7 13.8 43.1 96.6 100.0
caspofungin 3.4 6.9 44.8 89.7 96.6 100.0
Micafungin 1.7 8.6 63.8 96.6 98.3 100.0
C. kefyr  37 anidulafungin 2.7 10.8 56.8 100.0
caspofungin 13.5 97.3 100.0
Micafungin 5.4 40.5 100.0
C. famata 24 anidulafungin 4.2 16.7 20.8 20.8 20.8 25.0 50.0 100.0
caspofungin 4.2 12.5 20.8 37.5 70.8 70.8 95.8 100.0
Micafungin 4.2 16.7 16.7 20.8 33.3 75.0 91.7 100.0
Candida spp. 30 anidulafungin 3.3 30.0 50.0 63.3 63.3 73.3 86.7 93.3 96.7 96.7 100.0
caspofungin 16.7 43.3 63.3 73.3 96.7 100.0
Micafungin 20.0 53.3 66.7 66.7 86.7 100.0
total 5,246 anidulafungin 3.7 21.1 48.9 72.6 82.0 83.4 84.7 88.7 98.8 99.9 100.0
caspofungin 1.2 19.7 59.4 79.6 84.0 91.9 98.1 99.7 99.9 99.9 100.0
Micafungin 8.8 60.9 75.6 81.3 83.3 85.0 88.5 97.0 100.0
avalues corresponding to MIcs at which at least 90% of isolates are inhibited are listed in bold types.
Table 6. In vitro antifungal agent susceptibilities of Candida and Cryptococcus isolates collected by the sEntRy Program in 2006 to
2007 [39].
species (no. of isolates) MIc50/MIc90 (ﾵg/ml) MIc range (ﾵg/ml) % by categorya
and drug s sdd Rb
C. parapsilosis (238)
anidulafungin 2/2 0.03-4 95.4 – 4.6
caspofungin 0.5/1 0.06-4 99.6 – 0.4
amphotericin B 1/1 0.25-1 99.6 – 0.4
5-fc ≤0.5/≤0.5 ≤0.5->64 98.7 (0.0) 1.3
fluconazole 1/4 ≤0.5-32 96.6 3.4 0.0
Itraconazole 0.25/0.25 ≤0.015-2 40.8 57.1 2.1
Posaconazole 0.12/0.25 ≤0.06-1 –––
voriconazole ≤0.06/0.12 ≤0.06-2 99.6 0.4 0.0
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echinochandins [28].
It should be noted that there is at least for flucona-
zole a clear relation between MIc values, pharmacoki-
netics (expressed in serum auc) and outcome (fig. 4)
[29]. since resistance development against i.e. echino  -
candines so far is very limited, it is obviously very dif-
ficult to establish such a correlation. this problem is
further aggravated by the fact that current antifungals
still leave much to be desired as they i.e. do not reach
the cure rates of antibacterial agents for susceptible
bacteria.  Moreover,  the  described  resistance  mecha-
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Table 7. antifungal susceptibilities of rare Candida bloodstream isolates [41].
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clinical failure of the involved patients [30-35]. this
has raised concern over the cBP as suggested by the
clsI. for a discussion of this subject see [36, 37].
REsIstancE suRvEIllancE
among the worldwide largest and long run surveillance
systems is the aRtEMIs program.  In a recent publica-
tion [9], comparative susceptibility data for fluconazole
and voriconazole for more than 190,000 isolates col-
lected from 2001 to 2007 were provided and analysis of
resistance  rates  by  year,  geographic  location,  hospital
location, and specimen type for selected species were
included. the data were collected employing the clsI
disk diffusion method and are summarized in table 4.
they show that fluconazole resistance has to be expect-
ed especially in C. glabrata, krusei, guillermondii, fama-
ta, inconspicua, rugosa, norvegensis and some other rarer
species. there seem to be some but no complete cross-
resistance with voriconazole which leaves the latter as
an  option  in  appropriate  cases.  a  trend  toward  in-
creased resistance over the most recent 3 years (2005 to
2007) was observed for voriconazole and some species
with low prevalence such as C. famata (1.1% to 5.7%),
C.  norvegensis (0.0% to 6.9%), C.  lipolytica (0.0% to
11.1%), and C. pelliculosa (14.3% to 16.7%). However,
there  was  no  trend  toward  increased  resistance  to
voriconazole  among  the  fluconazole-resistant  species
C. glabrata, C. krusei, C. guilliermondii, C. rugosa, and
C. inconspicua. 
MIc  distributions  for  echinocandins  have  been
published by Pfaller et al. (table 5) [39]. the results of
this study demonstrate the comparable spectrum and
potency of all three available echinocandin antifungals
against a large collection of clinically important Candi-
da spp. It also highlights the fact that species such as
C. parapsilosis and C. guilliermondii exhibit decreased
susceptibilities to all three echinocandins. the clinical
relevance  of  these  elevated  MIcs  currently  remains
doubtful. 
the  data  collected  by  the  sEntRy  surveillance
program were published as MIc50/90 values and in-
terpreted  results  according  to  clsI,  only  [39,  40].
However, this study included most important antifun-
gals. an excerpt for C. parapsilosis is given with table
6. german data were published in the same way [15],
not offering significant differences to the sEntRy re-
sults with the exception of a high degree of flucyto-
sine resistance in C. krusei and C. tropicalis. finally,
susceptibility data for rare Candida isolates have been
collected by diekema et al. [41] (table 7) and chen et
al. [42] that might help to guide therapy in these cases.
conclusIon
Meanwhile in vitro methods are available to assess reli-
ably  the  susceptibility  of  fungal  isolates.  there  are,
however, considerable differences in the evaluation of
the results, as clsI and Eucast breakpoints vary. If
isolates with known resistance mechanisms that have
been shown to be clinically relevant at least in individ-
ual cases shall not be categorized as susceptible, some
clsI cBP need to be reconsidered. despite the fact
that a number of new antifungals are nowadays avail-
able, clinical results of antifungal therapy leave much
to be desired. Hence, optimization of empiric therapy
according  to  the  local  epidemiological  situation  and
reevaluation of the therapeutic regimen when suscep-
tibility results become available should carefully be fol-
lowed. With our expanded knowledge on pharmacoki-
netics of antifungal compounds, MIc data could be
valuable at least when treating invasive fungal infec-
tions. More information about MIcs of clinical iso-
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Fig.  4.  Mortality  rate  stratified  by  tertiles  and  fluconazole
auc/MIc at 24 h (P = 0.09 using logistic regression control-
ling for time to initiation of fluconazole therapy) [29].
Table 7 continued
7) Rodloff_Umbruchvorlage  23.03.11  12:41  Seite 193lates and outcome of the particular patients would be
helpful to establish further and validate current cBP. 
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